As of Jun 21
| +0.004 / +0.42%|
The 3 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 6.00, with a high estimate of 7.00 and a low estimate of 1.24. The median estimate represents a +532.18% increase from the last price of 0.95.
The current consensus among 6 polled investment analysts is to Hold stock in Regulus Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.